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Summary A combination ofcyclophosphamide, doxorubicin, vincristine and prednisolone (CHOP) has been a
standard therapy for histologically aggressive non-Hodgkin's lymphomas for over 20 years, but several newer
regimens, referred to as second or third generation, have been reported to give improved results in single-centre
studies. Positive evidence from randomised trials has been lacking, and the British National Lymphoma
Investigation therefore commenced a randomised comparison of CHOP vs a third-generation regimen,
PACEBOM, in November 1987. A total of 459 eligible patients were entered into the trial: 226 in the CHOP
arm and 233 in the PACEBOM arm. Overall, there was no significant difference in outcome between the two
arms of the trial. In patients with stage IV disease there was an apparent improvement in survival for those
treated with PACEBOM, but considerable caution must be exercised with such subgroup analysis.
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The incidence of the non-Hodgkin's lymphomas appears to
be rising in the developed world, and is now approximately 6/
100 000 in the European community and 10/100 000 in the
US (Esteve et al., 1993). Approximately one-third of patients
with histologically aggressive disease can be cured by
combination chemotherapy, and this has been seen as one
of the major successes for cancer therapy in the last 20 years.
McKelvey et al. (1976) reported on the successful use of a
combination of cyclophosphamide, doxorubicin, vincristine
and prednisone (CHOP), and this has since been considered
as standard therapy. During the 1980s second-and third-
generation regimens were introduced, which in non-rando-
mised studies from single centres suggested improved
outcome (Mathe et al., 1974; Fisher et al., 1983, 1984;
Shipp et al., 1986). These regimens include a larger number
of agents and a higher relative dose intensity (Hryniuk, 1988).
A particularly high complete remission (CR) rate (84%)
and 3 year overall survival (76%) was reported with the
MACOP-B regimen, which used six drugs given in alternating
weekly cycles of myelosuppressive and non-myelosuppressive
agents for 11 weeks (Klimo and Connors, 1985). This
regimen was developed in accord with the model of tumour
resistance proposed by Goldie et al. (1982).
In an attempt to improve the efficacy and reduce the
toxicity of MACOP-B, Sweetenham et al. (1991) developed
the PACEBOM regimen, which incorporates etoposide,
which has proven anti-lymphoma activity (Cecil et al.,
1978), and reduced the doses of methotrexate and
corticosteroids, which were thought to be the major source
of toxicity with the MACOP-B regimen. The PACEBOM
regimen was reasonably well tolerated, and in a small study
of 61 patients with advanced disease the average relative dose
intensity delivered was 87% of the planned dose (Sweet-
enham et al., 1991).
Between 1987 and 1992 the British National Lymphoma
Investigation carried out a randomised trial of CHOP vs
PACEBOM. The results reported here suggest a possible
advantage for PACEBOM in those patients with stage IV
disease.
Methods
Patients
Between November 1987 and October 1992, 471 patients were
enteredintothistrial. Theentrycriteria were agebetween 16and
69 years, previouslyuntreatedhistologicallyaggressive lympho-
ma with a large cell component (diffuse large cell, diffuse
immunoblasticanddiffusemixedcelllymphomas)andstage II -
IV. Patients with Burkitt's and lymphoblastic lymphoma were
excluded. All patients had to be free from non-lymphoma-
related disorders that would prohibit the administration ofthe
prescribed therapy and had to give informed consent. Ethics
committee approval was obtained in all participating centres.
Histological review was performed by the central BNLI panel.
Staging was carried out according to the Ann Arbor
classification. Computerised tomography (CT) scanning was
employed to detect intra-abdominal disease and laparotomy
was only carried out if necessary to make a diagnosis. Bone
marrow aspirate and trephine were required in the protocol for
all patients, but was not carried out, or the sample was
inadequate, in 12 patients (3%). These patients were not
excluded from the analysis and the stage is recorded as that
without taking the bone marrow result into account. Examina-
tion of cerebrospinal fluid was not required unless clinically
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February 1996indicated. Only one patient with overt central nervous system
disease at presentation was entered into the study.
Trial design
The CHOP regimen was 'a 2 weeks on, 2 weeks off cycle'
used by the BNLI since 1974 (Table I). A minimum of six
cycles was given with two courses beyond the attainment of
CR. The PACEBOM regimen was a seven-drug regimen
given in weekly alternating cycles of potentially non-cross-
resistant drugs over 11 weeks, as previously described
(Sweetenham et al., 1991) (Table I). The hypothetical relative
intensity compared with a standardised nine-drug regimen
(De Vita, 1987) was calculated as previously described
(Hryniuk, 1988) and was 0.31 for the CHOP regimen and
0.54 for PACEBOM. Allopurinol was given for the first 4
weeks of therapy. Cotrimoxazole 1 tablet b.d. was given for
14 weeks in the PACEBOM arm from November 1988
following three episodes of pneumocystis pneumonia in the
first year of the trial. Prophylactic antibiotics were not given
with CHOP. The dose modifications for haematological
toxicity are shown in Tables II and III.
Table I Treatment protocol
Cyclophosphamide 750mgm-2 day 1 and 8
Hydroxydaunorubicin (doxorubicin) 25mgm 2
day 1 and 8
Oncovin (vincristine) 1.4mgm-2 day 1 and 8
(max. dose 2mg)
Prednisolone 50mgM 2 day 1-8
Repeat course every 28 days from day 1.
PACEBOM Prednisolone 50mgday-1 week 1-4, 50mg
alternate days week 5-12
Adriamycin (doxorubicin) 35mgm 2 i.v. day 1
Cyclophosphamide 300mgm2 i.v. day 1
Etoposide l50mgm-2 i.v. day 1
Bleomycin 10mgm-2 i.v. day 8
Vincristine (oncovin) 1.4mgm 2 i.v. day 8
Methotrexate I00 mgm-2 i.v. day 8.
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It should be noted that in the original description of the
PACEBOM protocol (Sweetenham et al., 1991) the lower
neutrophil limit at which the drugs were delayed was
0.1 x 109 1-' rather than 0.3 x I09 1-' used in this study.
In both arms of the study the doxorubicin dose was
reduced to 50% if the bilirubin was raised between 35 and
50 mmol I` and reduced to 25% if the bilirubin was greater
than 50 mmol `'.
Response evaluation
All patients were assessed for response at 3 months after the
start of therapy. This was to include all previously abnormal
investigations. Further assessment was carried out at the end of
therapy and 3 months later. All patients werethencontinuously
followed up (one lost), and the frequency of repeat
investigations varied according to individual centre practice.
Complete remission (CR) was defined as the complete
disappearance of all clinical disease manifestations and the
reversal of all previously abnormal investigations maintained
for at least 3 months after the completion of therapy. Partial
remission (PR) was defined as the reduction of at least 50%
in the sums of the products of biperpendicular diameters of
known disease by the end of therapy. 'No response' (NR)
was defined as any response less than PR. Patients not
attaining a CR at the end of therapy or progressing during
therapy were given further treatment at the physician's
discretion.
Statistical methods
The trial was planned to accrue at least 375 patients. This
gave a 90% chance of detecting an overall improvement in
survival rate of 15% at the 5% significance level assuming the
5 year survival in the CHOP arm was 45% (Freedman, 1982),
which is in line with historical data.
Complete remission rates were compared by the use of a
chi-square test, with Yates' correction (Yates, 1934). Survival
curves were calculated by the life-table method, and statistical
comparison of curves performed by the log-rank test as
described by Peto et al. (1971). Adjustment of plot for
imbalances in the frequency distribution of variables in the
Table II Dose modifications of CHOP regimen for haematological toxicity
Neutrophils Platelets Cyclophosphamide Doxorubicin Vincristine Prednisolone
(x109r1) (xlO9 r) % (%)
First course
Day 1 >1.5 >100 100 100 100 100
< 1.5 < 100 50 50 100 100
Day 8 >1.5 >100 100 100 100 100
1 -1.5 75-100 50 50 100 100
< 1 <75 0 0 100 100
Subsequent courses
Day 1 >1.5 >100 100 100 100 100
1 -1.5 75-100 75 75 75 75
0.5-1 50-75 50 50 50 50
<0.5 <50 Delay for 1 week only and give 50%
Day 8 >1.5 >100 100 100 100 100
1 -1.5 75- 100 50 50 50 50
0.5-1 50-75 0 0 0 0
<0.5 <50 Delay for 1 week only and give 50%
Table III Dose modification of PACEBOM regimen for haematological toxicity
Neutrophils Cyclophospamide Doxorubicin Etoposide Metrotrexate Bleomycin Vincristine
(x109VI) (% (% (% (% (% (%
>1 100 100 100 100 100 100
0.3- 1 65 65 65 65 100 100
<0.3 Delay all drugs for 1 week
No dosage reduction for low platelet count.
CHOPComparison of PACEBOM and CHOP
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two arms of the trial was performed by the method described
by Gregory (1988). Prognostic factors were analysed by
means of a proportional hazards model (Cox, 1972).
A limited set of possible interactions between prognostic
factors and treatment were considered for cause-specific
survival. Three factors found to be significant in the
multivariate survival analysis, namely age, Karnofsky index
and stage, were assessed. The Cox model was fitted both with
and without interactions, and the improvement in fit
evaluated using the likelihood ratio test (Byse, 1989).
Results
Patients
Between November 1987 and October 1992 471 patients were
entered into this trial. Following histological review 12
patients were excluded leaving a total of 459 patients. There
were 401 patients with diffuse large-cell lymphoma including
immunoblastic lymphomas and 58 with diffuse mixed. A total
of 226 patients were randomised to receive CHOP and 233 to
receive PACEBOM. The demographics of the two patient
groups were similar (Table IV).
Protocol violations
Eleven patients in the CHOP arm (5%) had major protocol
violations. These included unscheduled chemotherapy in four
patients (one given PACEBOM) and consolidation radio-
therapy (RT) in first CR in seven patients. In the PACEBOM
arm there were 11 major protocol violations (5%); three
patients were given unscheduled chemotherapy (two given
CHOP) and eight were given consolidation RT in first CR.
Table IV Patient demographics
Chop Pacebom
Number 226 233
Age
<50 years 94 (42%) 85 (37%)
>50 years 132 (59%) 147 (63%)
Sex
Male 146 (65%) 139 (60%)
Female 80 (35%) 94 (40%)
Stage
II 79 (35%) 74 (32%)
III 53 (23%) 53 (23%)
IV 94 (42%) 106 (45%)
B symptoms 112 (50%) 117 (50%)
Marrow involvement 35 (16%) 39 (17%)
Mediastinal involvement 77 (28%) 66 (29%)
Karnofsky score <80 62/215 (29%) 61/228 (27%)
The analysis is made on an 'intention to treat' basis and these
patients were not excluded.
Regimen toxicity
There were three procedure-related deaths in the CHOP arm
(1%), one due to haemorrhage and two to sepsis. In the
PACEBOM arm there were four septic deaths (2%). A total
of 34% of patients in the CHOP arm were recorded as
having WHO grade III/IV haematological toxicity compared
with 50% in the PACEBOM arm (P=0.02).
Overall response rates
In the CHOP arm 57% ofpatients achieved a CR, 31% a PR
and 12% had no response. In the PACEBOM arm 64% of
patients achieved a CR and 27% a PR. The 9% NRs
includes one patient who died of sepsis after 11 weeks of
treatment with no clinical evidence of disease but before full
restaging was carried out. No post mortem was performed.
The difference in overall CR rate between the CHOP and
PACEBOM arms was not significant (P=0.14).
Survival analysis
The actuarial CR -relapse-free percentage at 5 years was
59% and 67% in the CHOP and PACEBOM arms
respectively [P=0.91, 95% confidence intervals (CI) 47-70
and 58-75 respectively, Figure 1]. Eight patients in the
CHOP arm relapsed with CNS disease but in only three was
this localised to the CNS. In the PACEBOM arm there
were four CNS relapses, one of which was restricted to the
CNS. The actuarial overall survivals at 5 years in the
CHOP and PACEBOM arms were 47% and 56%
respectively (P =0.23, CI 39-56 and 48-63, Figure 2).
The actuarial cause-specific survivals from non-Hodgkin's
lymphoma at 5 years were 50% and 60% (P=0.18, CI 41-
58 and 52-68, Figure 3). There were four intercurrent
deaths in the CHOP arm, one due to a myocardial infarct,
one to ischaemic heart disease and a cerebrovascular
accident, one to carcinoma of the bronchus and one to
acute myeloid leukaemia. In the PACEBOM arm there were
five intercurrent deaths; two due to myocardial infarction,
one to pulmonary fibrosis in a patient with severe
rheumatoid arthritis, one to acute myeloid leukaemia and
one sudden death of unknown cause.
Subgroup analysis
Patients were evaluated according to prognostic factors
(Table V). It should be noted that on univariate analysis
the stage most informatively predicting for survival was stage
IV rather than stage III/IV as in the age-adjusted
international index (The International Non-Hodgkin's
Lymphoma Prognostic Factors Project, 1993) and the age
threshold was 50 years rather than 60 years, and these cut-off
points were used in the multivariate analysis. Lactate
Table V Potential prognostic factors considered
Proportion ofpatientsfor which
Variable Covariates/Cut-offpoints information was available (%)
Age <50, 50-59, 60-79, 70+ 100
Sex M, F 100
Stage II, III, IV 100
Pathology Large cell, diffused mixed 96.7*
B symptoms A, B 99.5
Haemoglobin < 12, 12+ 98.5
Mediastinal involvement Involved, not involved 97.4
Karnofsky score <80, 80+ 96.5
Serum albumin <36, 36+ 96.0
ESR <40, 40+ 78.6
*In 15 cases amalignant lymphomawith a large cell component was diagnosed but the subtype
was not given.Comparison of PACEBOM and CHOP
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Figure 1 Percentage of patients in complete remission remaining
relapse-free. Number of patients at risk shown at lower left.
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Figure 3 Cause-specific survival. Number of patients at risk
shown at lower left.
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PACEBOM (n= 233) comparing CHOP with m-BACOD, Pro-MACE CytaBOM and MACOP-B, and this concluded that there was no
siznificant advantaze to anv regimen (Fisher et al.. 1993).
In the current study the British National Lymphoma
CHOP (n= 226) Investigation (BNLI) has compared CHOP with PACEBOM.
174 131 90 52 23 Overall, there was no significant difference in outcome
164 112 76 48 17 between the two arms. Univariate analysis suggested that
PACEBOM was superior to CHOP in younger patients and
2 4 6 8 10 in patients with stage IV disease. There was also a trend towards improved cause-specific survival with PACEBOM in
Time (years) the age-adjusted international index poor-prognosis group
(0.06). It is noteworthy that stage IV and age over 50 years
Overall survival. Number of patients at risk shown at were more predictive of poor prognosis than stage III/IV and
age over 60 years as used in the international index. In part
this may be because stage I patients were excluded from this
trial, as were patients over the age of 69 years.
In the SWOG/ECOG study there was apparently no
:nase (LDH) was not included as it was not significant advantage to any ofthe third generation regimens,
in a large number of patients in the early stages even when the subgroup of poor-prognosis patients was
al. Multivariate analysis of the series as a whole evaluated. The difference from the current trial may relate to
,nificant factors for low cause-specific survival to be the different criteria used to identify poor-risk patients, but a
index <80 [relative risk (RR)=2.2, 95% number of other possibilities exist.
intervals (CI) 1.6-3.0, P<0.0001], age >,50 Firstly, the BNLI CHOP regimen is not the same as that
95% CI 1.5-3.0, P < 0.0001) and stage IV used in the SWOG/ECOG study. The latter regimen gives
95% CI 1.2-2.3, P=0.001). On univariate intravenous cyclophosphamide, doxorubicin and vincristine
ACEBOM was superior to CHOP in patients with on day 1 followed by a 21 day gap. In the BNLI protocol
lisease (P=0.03) and in patients <50 years of age these drugs are given (at a lower dose of cyclophosphamide
and doxorubicin) on day 1 and 8 followed by a 21 day gap.
to the missing LDH values referred to above only The theoretical relative dose intensity for the SWOG/ECOG
ltS under the age of 60 years could be categorised CHOP over the first 12 weeks is 0.26, compared with 0.31 for
and good-prognosis groups using the age-adjusted the BNLI CHOP. The total planned dose of drugs
aal index for non-Hodgkin's lymphoma, where administered in BNLI CHOP is significantly greater than
,nosis in patients aged 60 or under is defined as 2 that in the SWOG/ECOG CHOP. The complete remission
"age III/IV, a Karnofsky score less than 80 and a rate in the CHOP arm in the current study was 57% with an
H. [Analysis ofpatients in whom the LDH was not overall survival at 3 years of 58%. This compares favourably
did not reveal significant differences in other with a CHOP-induced complete remission rate of 44% and
s compared with patients in whom it was overall survival at 3 years of 54% in the SWOG/ECOG study
apart from a slight increase in incidence of (Fisher et al., 1993), although it must be noted that the
d disease (P=0.04), which was itself not a patient groups may not have been directly comparable. The
indicator.] Using this index, the CR rate in the median age in the BNLI study was 54 years compared with
,nostic group was 47% compared with 75% in the 56 years in the SWOG/ECOG study and the latter did
nosis group (P < 0.0001), and the overall survival contain some septuagenarians who were excluded from entry
was 44% and 76% in the poor and good groups to the BNLI study.
y (P< 0.001). However, the relapse rates were not Secondly, the apparent advantage for PACEBOM in stage
ly different in the two groups (27% and 23% IV disease in the current study might be due to chance,
ly, P=0.83). In the poor-risk group so defined there compounded by the fact that a subgroup analysis was
nd towards improved survival in the PACEBOM performed. The subgroup analysis was based on the poor
).06). prognostic factors identified in this trial by multivariate
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analysis. and was not therefore planned at the initiation of
the trial. Caution must therefore be exercised in the
interpretation of these results given the number of possible
subgroup comparisons and the fact that these were not
specified beforehand (Byse. 1989). It is also important to note
that if the difference in stage IV disease is real and is limited
to this subgroup, then the trial size may have been too small
to detect the difference in survival in the overall analysis.
Based on the observed improvement in cause-specific survival
of 20% at 4 years in stage IV disease, the improvement
overall would be approximately 10%. To have a 90% chance
of detecting this at the 5% level of significance would require
a trial with at least 830 patients (Freedman. 1982).
Thirdly. it is possible that the advantage seen with
PACEBOM is because PACEBOM is a superior therapy to
CHOP, and by inference to other third-generation regimens.
The PACEBOM regimen is a weekly alternating non-cross-
resistant regimen with a relative dose intensity of 0.54 which
is very similar to MACOP-B (0.51). The major difference is
the inclusion of etoposide in PACEBOM, although the
significance of this is not known. It would be of interest to
know the received dose intensities in this trial but these data
are not available.
As previously stated. it was not possible to analyse this
trial fully in terms of the international index as LDH levels
were not recorded in many patients. It was possible. however.
in the patients under 60 years of age to designate 231 patients
as either high risk or low risk on the index. This confirmed
that high-risk patients, so defined, have a lower CR rate and
overall survival. but it is noteworthy that there was little
difference in the relapse rate once a CR was attained. This
emphasises that future attempts to improve outcome in poor-
risk patients should address better initial therapy rather than
focus on consolidation therapy in patients who have already
attained a CR.
In conclusion, this trial has raised the possibility that
PACEBOM may be a superior therapy to CHOP in poor
prognosis patients with histologically aggressive non-Hodg-
kin's lymphoma. particularly in those patients with stage IV
disease. although caution must be exercised with subgroup
analyses.
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